Personalized Neoantigen Vaccines Trial
Revolutionary quantum computing trial for brain tumors. Phase I study using quantum algorithms to optimize drug combinations for glioblastoma.
Phase I Study of Quantum-Enhanced Drug Combinations in Advanced Brain Tumors
Full Title
A phase I, open-label, dose-escalation study of quantum computational algorithm-selected drug combinations in patients with recurrent glioblastoma or brain metastases from solid tumors
Purpose
Scientists use quantum computers to identify the best combinations of drugs to treat brain tumors. These powerful computers can analyze millions of possible drug combinations to find ones that work best together against brain cancer while causing fewer side effects.
Primary Objectives
- Determine the maximum tolerated dose of quantum-selected drug combinations
- Evaluate safety and tolerability of novel drug combinations
- Assess blood-brain barrier penetration and CNS pharmacokinetics
Diseases
- Brain Tumour
- Glioblastoma
- Brain Metastases
- Recurrent Brain Cancer
Who Can Join this Trial
To participate in this study, you must meet ALL of the following criteria
- Have histologically confirmed recurrent glioblastoma OR brain metastases from solid tumors
- Have progressive disease following standard treatment including surgery and/or radiotherapy
- Have undergone comprehensive molecular profiling for quantum algorithm analysis
- Karnofsky Performance Status ≥70%
- Age 18-70 years
- Life expectancy ≥12 weeks
- Stable or decreasing corticosteroid dose for at least 5 days
- Adequate bone marrow, hepatic, and renal function
- No evidence of significant intracranial hemorrhage on baseline MRI
Access Clinical Trials
Locations
CONTACT
📞 Call Now: 1-800-NEOVITA (1-800-636-8482)
🌐 Online Scheduling: Schedule Your Consultation
📧 Email: info@neovitaoncology.com